论文部分内容阅读
上野制药厂最近开发了一种特异的抗艾滋病病毒药,暂定名为UFC-A。并已在美国开始了临床试验。经美国国立癌症研究所证实:UFC-A 在试管内抗艾滋病病毒感染率接近100%。目前,各国正在竞相开发被称为“现代黑死病”的艾滋病治疗药,由于该物质显示出良好的抗病毒活性,可望促进今后的开发速度。UFC-A 是化学合成的有机物,其结构与现在正在研究的其他抗艾滋病病毒药有很大不同。其分子量等详细情况因没有得到特许暂不能公布,但看来不是十分复杂的化合物。这种物质进入细胞内后,通过
Ueno Pharmaceutical Factory has recently developed a specific anti-HIV drug, tentatively named UFC-A. And has begun clinical trials in the United States. The United States National Cancer Institute confirmed: UFC-A in vitro anti-HIV infection rate close to 100%. At present, all countries are racing to develop the AIDS treatment drug known as “modern black death”. As the substance shows good antiviral activity, it is expected to promote the development speed in the future. UFC-A is a chemically synthesized organism whose structure is very different from the other anti-HIV drugs currently under study. The details such as its molecular weight can not be announced without a license, but it does not appear to be a very complicated compound. After this substance enters the cell, it passes